Eliem Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

CLYM$11.74+6.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

Assets	June 30, 2024	December 31, 2023
Current assets:
Cash and cash equivalents	$223,140	$93,112
Short-term marketable securities	—	13,686
Prepaid expenses and other current assets	2,857	3,457
Total current assets	$225,997	$110,255
Operating lease right-of-use assets	21	199
Other long-term assets	—	15
Total assets	$226,018	$110,469
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	509	66
Accounts payable, related party	101	—
Accrued expenses and other current liabilities	2,950	2,433
Accrued expenses and other current liabilities, related party	81	—
Operating lease liabilities	100	334
Total current liabilities	$3,741	$2,833
Operating lease liabilities, net of current portion	—	22
Other long-term liabilities	—	15
Total liabilities	$3,741	$2,870
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock, $0.0001 par value per share, 250,000,000 shares authorized; 66,785,449 and 27,699,446 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	7	3
Additional paid-in capital	434,835	263,577
Accumulated other comprehensive loss	—	(2)
Accumulated deficit	(212,565)	(155,979)
Total stockholders’ equity	$222,277	$107,599
Total liabilities and stockholders’ equity	$226,018	$110,469

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.